Kintara Therapeutics (NASDAQ:KTRA) Shares Up 16.2%

Kintara Therapeutics, Inc. (NASDAQ:KTRA) was up 16.2% on Thursday . The company traded as high as $0.11 and last traded at $0.10. Approximately 32,156,478 shares traded hands during mid-day trading, an increase of 171% from the average daily volume of 11,885,169 shares. The stock had previously closed at $0.09.

Kintara Therapeutics Stock Up 16.2 %

The firm has a market capitalization of $4.06 million, a price-to-earnings ratio of -0.02 and a beta of 0.59. The stock’s 50 day moving average price is $0.11 and its two-hundred day moving average price is $1.13.

Kintara Therapeutics (NASDAQ:KTRA) last posted its quarterly earnings results on Wednesday, February 14th. The company reported ($0.24) earnings per share for the quarter. On average, equities analysts expect that Kintara Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Kintara Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC grew its position in shares of Kintara Therapeutics by 1,210.7% in the second quarter. Renaissance Technologies LLC now owns 722,400 shares of the company’s stock valued at $201,000 after purchasing an additional 667,284 shares during the last quarter. Advisor Group Holdings Inc. grew its position in shares of Kintara Therapeutics by 182.7% in the first quarter. Advisor Group Holdings Inc. now owns 73,367 shares of the company’s stock valued at $130,000 after purchasing an additional 47,415 shares during the last quarter. Susquehanna International Group LLP acquired a new stake in shares of Kintara Therapeutics in the first quarter valued at about $39,000. Finally, Morgan Stanley grew its position in shares of Kintara Therapeutics by 190.4% in the fourth quarter. Morgan Stanley now owns 4,252 shares of the company’s stock valued at $29,000 after purchasing an additional 2,788 shares during the last quarter. 0.62% of the stock is currently owned by institutional investors.

About Kintara Therapeutics

Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients.